ClinicalTrials.gg
CompletedNCT01188850Updated Aug 10, 2018

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

A Phase 1 interventional study of VGX-3100 in Human Papillomavirus (HPV), sponsored by Inovio Pharmaceuticals. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years to 46 Years. Per ClinicalTrials.gov, last updated 2018-08-10.

Sponsored by Inovio Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 46 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Enrollment
589th of 678
14 · median 71
Started
2010
with 21 others
Phase 1
168 of 834
22 open now
Registered
257th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 589th largest by enrollment of the 678 interventional ones that give a count, is one of 22 that started in 2010, is one of 168 in phase 1, and was the 257th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

140 more — sign in →

All 145 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 46 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines. DNA vaccines appear to be well tolerated in humans. Therefore, the investigators have developed our DNA vaccine, VGX-3100, to include plasmids targeting E6 and E7 proteins of both HPV subtypes 16 and 18. The investigators have chosen to deliver our candidate vaccines via electroporation (EP) using the CELLECTRA constant current device to deliver a small electric charge following intramuscular (IM) injection, since animal studies have shown that this delivery method increases the immune response to our DNA vaccine leading to a decrease in the size of tumors caused by HPV 16 and 18. In study HPV-001, the vaccine was given to subjects with a history of CIN 2 and 3 who had been previously treated by surgery. This study is proposed to vaccinate the same subjects with a fourth dose of the VGX-3100 to determine the safety and immune response.

03

Conditions studied

  • Human Papillomavirus (HPV)

Keywords

  • CIN 2 or 3
  • cervical cancer
  • Human Papillomavirus (HPV)
04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written in accordance with institutional guidelines;
  2. Successful enrollment in and completion of all study procedures and follow-up in study HPV-001.
  3. Female 18-46 years of age;
  4. Post surgical (including LEEP and conization) or ablative treatment and a diagnosis of CIN 2 or 3, while under physician care as per ASCCP guidelines (Appendix C);
  5. Normal and CPK, as judged by Grade 0-1 as per Toxicity Grading Scale for Healthy Adults (Appendix B) done up to 30 days prior to administration of study treatment;
  6. (BMI) ≤30 kg/m2;
  7. Women of (WOCBP) agree to remain sexually abstinent, use medically effective (oral contraception, barrier methods, spermicide, etc), or have a partner who is sterile (i.e., vasectomy) from enrollment to study discharge;
  8. Able and willing to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Active infection with herpes simplex virus (HSV);
  2. Pregnant or breast feeding subjects;
  3. Any concurrent condition requiring the continued use of systemic or topical (excluding inhaled and eye drop-containing corticosteroids) or the use of agents. All other corticosteroids must be discontinued > 4 weeks prior to Day 1 of treatment;
  4. Administration of any blood product within 3 months of enrollment;
  5. Administration of any vaccine within 6 weeks of enrollment;
  6. Patient is currently participating or has participated in a study with an compound or device other than VGX-3100 within 30 days of signing ;
  7. Metal implants at the site of injection;
  8. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
  9. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
  10. Any other conditions judged by the investigator that would limit the evaluation of a subject.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    6mg of DNA/dose

    Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0

    Biological: VGX-3100

Interventions

  • BiologicalVGX-3100

    DNA plasmid delivered via IM injection + electroporation using CELLECTRA device

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of a fourth dose of VGX-3100

    Safety and tolerability of a fourth dose of VGX-3100, administered by IM injection with EP to adult females who have been previously immunized with three doses of VGX-3100

    Time frame: through Month 6 (end of study)

Secondary outcomes

  1. Humoral and cellular immune responses to VGX-3100

    Humoral and cellular immune responses to VGX-3100 in blood samples obtained from study subjects after a fourth dose of VGX-3100 (6 mg) in adult female subjects who have been previously vaccinated with a three dose series of VGX-3100 containing 0.6, 2 or 6 mg of DNA/dose.

    Time frame: through Month 6 (end of study)

07

Study locations

3 sites
  • Lyndhurst Gynecologic Associates
    Winston-Salem, North Carolina 27103, United States
  • Laurel Highlands, OB/GYN, P.C.
    Hopwood, Pennsylvania 15904, United States
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 26, 2010
Start
Jul 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 20, 2011
Last update
Aug 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01188850
Responsible party
Sponsor
First posted
Aug 26, 2010
Start date
Jul 2010
Primary completion
Oct 2011
Completion
Oct 20, 2011
Last update
Aug 10, 2018

Study contacts

Robert Parker, MD
principal investigator · Lyndhurst Gynecologic Associates
John Sunyecz, MD
principal investigator · Laurel Highlands, OB/GYN, P.C.
Javier Morales, MD
principal investigator · Clinical Research Puerto Rico

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VGX-3100

Start the discussion